FDA panel votes on the potential removal from the market of Makena; anticoagulants compared in patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the Novavax COVID-19 vaccine becomes the latest authorized booster; and the review periods for investigational treatments for nephropathy and ALS have been extended.